Green Valley's oligosaccharide meets in Phase III for AD

Shanghai Green Valley Pharmaceutical Co. Ltd. (Shanghai, China) said GV-971 (sodium oligomannurarate) met the primary endpoint of improving Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog) score from baseline to week 36 vs. placebo in a Phase III trial to treat mild to moderate AD. The company plans to submit a regulatory application for the oligosaccharide inhibiting β amyloid aggregation to China's State Drug Administration this year...